Research protocol of two concurrent cluster-randomized trials: Real-life Effect of a CAMPaign with Measles Vaccination (RECAMP-MV) and Real-life Effect of a CAMPaign with Oral Polio Vaccination (RECAMP-OPV) on mortality and morbidity among children in rural Guinea-Bissau

A Varma, A K G Jensen, S M Thysen, L M Pedersen, P Aaby, A B Fisker, A Varma, A K G Jensen, S M Thysen, L M Pedersen, P Aaby, A B Fisker

Abstract

Background: Measles and oral polio vaccinations may reduce child mortality to an extent that cannot be explained by prevention of measles and polio infections; these vaccines seem to have beneficial non-specific effects. In the last decades, billions of children worldwide have received measles vaccine (MV) and oral polio vaccine (OPV) through campaigns. Meanwhile the under-five child mortality has declined. Past MV and OPV campaigns may have contributed to this decline, even in the absence of measles and polio infections. However, cessation of these campaigns, once their targeted infections are eradicated, may reverse the decline in the under-five child mortality. No randomized trial has assessed the real-life effect of either campaign on child mortality and morbidity. We present the research protocol of two concurrent trials: RECAMP-MV and RECAMP-OPV.

Methods: Both trials are cluster-randomized trials among children registered in Bandim Health Project's rural health and demographic surveillance system throughout Guinea-Bissau. RECAMP-MV is conducted among children aged 9-59 months and RECAMP-OPV is conducted among children aged 0-8 months. We randomized 222 geographical clusters to intervention or control clusters. In intervention clusters, children are offered MV or OPV (according to age at enrolment) and a health check-up. In control clusters, children are offered only a health check-up. Enrolments began in November 2016 (RECAMP-MV) and March 2017 (RECAMP-OPV). We plan 18,000 enrolments for RECAMP-MV with an average follow-up period of 18 months and 10,000 enrolments for RECAMP-OPV with an average follow-up period of 10 months. Data collection is ongoing. The primary outcome in both trials is non-accidental death or non-accidental first non-fatal hospitalization with overnight stay (composite outcome). Secondary outcomes are: non-accidental death, repeated non-fatal hospitalizations with overnight stay, cause-specific primary outcome, outpatient visit, and illness. We obtained ethical approval from Guinea-Bissau and consultative approval from Denmark.

Discussion: Cluster randomization and minimum risk of loss to follow-up are strengths, and no placebo a limitation. Our trials challenge the understanding that MV and OPV only prevent measles and polio, and that once both infections are eradicated, campaigns with MV and OPV can be phased out without negative implications on child health and survival.

Trial registration: NCT03460002.

Conflict of interest statement

The authors declare that they have no competing interests.

Figures

Fig. 1
Fig. 1
Guinea-Bissau’s routine child vaccination program
Fig. 2
Fig. 2
Flowchart from eligibility to follow-up in RECAMP-MV and RECAMP-OPV. Abbreviations: MV = measles vaccination; OPV = oral polio vaccination; MUAC = mid-upper-arm circumference; Y/N/U = yes/no/unknown

References

    1. de Bree LCJ, Koeken VACM, Joosten LAB, Aaby P, Benn CS, van Crevel R, et al. Non-specific effects of vaccines: current evidence and potential implications. Semin Immunol. 2018;39:35–43. doi: 10.1016/j.smim.2018.06.002.
    1. Higgins JPT, Soares-Weiser K, Reingold A. Systematic review of the non-specific effects of BCG, DTP and measles containing vaccines Available from: . Accessed 17 Jul 2018.
    1. World Health Organization Meeting of the Strategic Advisory Group of Experts on immunization, April 2014 -- conclusions and recommendations. Wkly Epidemiol Rec. 2014;89(21):221–236.
    1. Lund N, Andersen A, Hansen AS, et al. The effect of Oral polio vaccine at birth on infant mortality: a randomized trial. Clin Infect Dis. 2015;61(10):1504–1511. doi: 10.1093/cid/civ617.
    1. Lund N, Biering-Sorensen S, Andersen A, et al. Neonatal vitamin A supplementation associated with a cluster of deaths and poor early growth in a randomised trial among low-birth-weight boys of vitamin A versus oral polio vaccine at birth. BMC Pediatr. 2014;14(1):214. doi: 10.1186/1471-2431-14-214.
    1. Mogensen SW, Andersen A, Rodrigues A, et al. The introduction of diphtheria-tetanus-pertussis and oral polio vaccine among young infants in an urban African community: a natural experiment. EBioMedicine. 2017;17:192–198. doi: 10.1016/j.ebiom.2017.01.041.
    1. Aaby P, Jensen H, Gomes J, et al. The introduction of diphtheria-tetanus-pertussis vaccine and child mortality in rural Guinea-Bissau: an observational study. Int J Epidemiol. 2004;33(2):374–380. doi: 10.1093/ije/dyh005.
    1. World Health Organization. Measles and Rubella Global Strategic Plan 2012-2020 Midterm Review. Available from: . Accessed 17 Jul 2018.
    1. World Health Organization. Polio Eradication & Endgame. Midterm Review July 2015. Available from: . Accessed 12 Mar 2019.
    1. World Health Organization. Measles vaccines. WHO position paper – April 2017. Wkly Epidemiol Rec 2017;92(17):205–227.
    1. World Health Organization Polio vaccines: WHO position paper – March, 2016. Wkly Epidemiol Rec. 2016;91(12):145–168.
    1. Hug L, Sharrow D, Zhong K, You D. Levels and trends in child mortality. Report 2018. Estimates developed by the UN Inter-agency group for child mortality estimation. Available from: . Accessed 14 Mar 2019.
    1. Fisker AB, Rodrigues A, Martins C, Ravn H, Byberg S, Thysen S, et al. Reduced all-cause child mortality after general measles vaccination campaign in rural Guinea-Bissau. Pediatr Infect Dis J. 2015;34(12):1369–1376. doi: 10.1097/INF.0000000000000896.
    1. Byberg S, Thysen SM, Rodrigues A, Martins C, Cabral C, Careme M, et al. A general measles vaccination campaign in urban Guinea-Bissau: comparing child mortality among participants and non-participants. Vaccine. 2017;35(1):33–39. doi: 10.1016/j.vaccine.2016.11.049.
    1. Andersen A, Fisker AB, Rodrigues A, et al. National Immunization Campaigns with Oral polio vaccine reduce all-cause mortality: a natural experiment within seven randomized trials. Front Public Health. 2018;6:13. doi: 10.3389/fpubh.2018.00013.
    1. Aaby P, Andersen A, Martins CL, et al. Does oral polio vaccine have non-specific effects on all-cause mortality? Natural experiments within a randomised controlled trial of early measles vaccine. BMJ Open. 2016;6(12):e013335. doi: 10.1136/bmjopen-2016-013335.
    1. Benn CS, Jacobsen LH, Fisker AB, et al. Campaigns with oral polio vaccine may lower mortality and create unexpected results. Vaccine. 2017;35(8):1113–1116. doi: 10.1016/j.vaccine.2016.11.006.
    1. Aaby P, Hedegaard K, Sodemann M, et al. Childhood mortality after oral polio immunisation campaign in Guinea-Bissau. Vaccine. 2005;23(14):1746–1751. doi: 10.1016/j.vaccine.2004.02.054.
    1. World Health Organization. Summary of Measles-Rubella Supplementary Immunuzation Activities 2000–2018. Available from: . Accessed 17 Jul 2018.
    1. World Health Organization. Reported incidence time series. Available from: . Accessed 17 Jul 2018.
    1. World Health Organization. Official country reported coverage estimates time series. Available from: . Accessed 17 Jul 2018.
    1. Polio Global Eradication Initiative. Polio-free countries. Available from: . Accessed 12 Mar 2019.
    1. Thysen Sanne Marie, Fernandes Manuel, Benn Christine Stabell, Aaby Peter, Fisker Ane Bærent. Cohort profile : Bandim Health Project’s (BHP) rural Health and Demographic Surveillance System (HDSS)—a nationally representative HDSS in Guinea-Bissau. BMJ Open. 2019;9(6):e028775. doi: 10.1136/bmjopen-2018-028775.
    1. Hornshøj Linda, Benn Christine Stabell, Fernandes Manuel, Rodrigues Amabelia, Aaby Peter, Fisker Ane Bærent. Vaccination coverage and out-of-sequence vaccinations in rural Guinea-Bissau: an observational cohort study. BMJ Open. 2012;2(6):e001509. doi: 10.1136/bmjopen-2012-001509.
    1. Thysen SM. Can earlier BCG vaccination reduce early infant mortality? A randomised trial (BCGR). Available from: . Accessed 12 Mar 2019.
    1. World Health Organization. Immunization surveillance, assessment and monitoring online country profiles. Available from: . Accessed 17 Jul 2018.
    1. Hayes RJ, Moulton LH. Sample size. Boca Raton, FL: Chapman & Hall/CRC; 2009. Cluster randomised trials; pp. 105–127.
    1. INDEPTH network. Indepth verbal autopsy. Available from: . Accessed 17 Jul 2018.
    1. Martins CL, Benn CS, Andersen A, Balé C, Schaltz-Buchholzer F, Do VA, et al. A randomized trial of a standard dose of edmonston-zagreb measles vaccine given at 4.5 months of age: effect on total hospital admissions. J Infect Dis. 2014;209:1731–1738. doi: 10.1093/infdis/jit804.
    1. World Health Organization. Information Sheet Observed Rate of Vaccine Reactions Measles, Mumps and Rubella Vaccines. Available from: . Accessed 17 Jul 2018.
    1. Chuang SK, Lau YL, Lim WL, Chow CB, Tsang T, Tse LY. Mass measles immunization campaign: experience in the Hong Kong Special Administrative Region of China. Bull World Health Organ. 2002;80(7):585–591.
    1. Abedi GR, Mutuc JD, Lawler J, Leroy ZC, Hudson JM, Blog DS, et al. Adverse events following a third dose of measles, mumps, and rubella vaccine in a mumps outbreak. Vaccine. 2012;30(49):7052–7058. doi: 10.1016/j.vaccine.2012.09.053.
    1. Arruda WO, Kondageski C. Aseptic meningitis in a large MMR vaccine campaign (590,609 people) in Curitiba, Parana, Brazil, 1998. Rev Inst Med Trop Sao Paulo. 2001;43(5):301–302. doi: 10.1590/S0036-46652001000500012.
    1. Roberts RJ, Sandifer QD, Evans MR, Nolan-Farrell MZ, Davis PM. Reasons for non-uptake of measles, mumps, and rubella catch up immunisation in a measles epidemic and side effects of the vaccine. BMJ. 1995;310(6995):1629–1632. doi: 10.1136/bmj.310.6995.1629.
    1. Strebel PM, Papania MJ, Dayan GH, Halsey NA. Measles vaccines. Philadelphia: Saunders/Elsevier; 2008. Vaccines; pp. 353–398.
    1. Sugawara T, Ohsuka Y, Taya K, et al. Diarrhea as a minor adverse effect due to oral polio vaccine. Jpn J Infect Dis. 2009;62(1):51–53.
    1. Cessation of use of trivalent oral polio vaccine and introduction of inactivated poliovirus vaccine worldwide, 2016. Wkly Epidemiol Rec. 2016;91(36–37):421–7.
    1. Update on vaccine-derived polioviruses worldwide, January 2015–May 2016. Wkly Epidemiol Rec. 2016;91(31):365–75.
    1. Aaby P, Andersen M, Sodemann M, Jakobsen M, Gomes J, Fernandes M. Reduced childhood mortality after standard measles vaccination at 4-8 months compared with 9-11 months of age. BMJ. 1993;307(6915):1308–1311. doi: 10.1136/bmj.307.6915.1308.
    1. Aaby P, Martins CL, Garly ML, Balé C, Andersen A, Rodrigues A, et al. Non-specific effects of standard measles vaccine at 4.5 and 9 months of age on childhood mortality: randomised controlled trial. BMJ. 2010;341:c6495. doi: 10.1136/bmj.c6495.
    1. Desgrees du Lou A, Pison G, Aaby P. Role of immunizations in the recent decline in childhood mortality and the changes in the female/male mortality ratio in rural Senegal. Am J Epidemiol. 1995;142(6):643–652. doi: 10.1093/oxfordjournals.aje.a117688.
    1. Aaby P, Jensen H, Samb B, Cisse B, Sodemann M, Jakobsen M, et al. Differences in female-male mortality after high-titre measles vaccine and association with subsequent vaccination with diphtheria-tetanus-pertussis and inactivated poliovirus: reanalysis of West African studies. Lancet. 2003;361(9376):2183–2188. doi: 10.1016/S0140-6736(03)13771-3.
    1. Aaby P, Garly ML, Bale C, Martins C, Jensen H, Lisse I, et al. Survival of previously measles-vaccinated and measles-unvaccinated children in an emergency situation: an unplanned study. Pediatr Infect Dis J. 2003;22(9):798–805. doi: 10.1097/01.inf.0000083821.33187.b5.
    1. Nielsen BU, Byberg S, Aaby P, Rodrigues A, Benn CS, Fisker AB. Seasonal variation in child mortality in rural Guinea-Bissau. Tropical Med Int Health. 2017;22(7):846–856. doi: 10.1111/tmi.12889.
    1. Jensen K. J., Ndure J., Plebanski M., Flanagan K. L. Heterologous and sex differential effects of administering vitamin A supplementation with vaccines. Transactions of the Royal Society of Tropical Medicine and Hygiene. 2014;109(1):36–45. doi: 10.1093/trstmh/tru184.
    1. Aaby P, Andersen A, Martins CL, Fisker AB, Rodrigues A, Whittle HC, et al. Does oral polio vaccine have non-specific effects on all cause mortality? Natural experiments within a randomized controlled trial of early measles vaccine. BMJ Open. 2016;6(12):e013335. doi: 10.1136/bmjopen-2016-013335.
    1. Andersen A, Bjerregaard-Andersen M, Rodrigues A, et al. Sex-differential effects of diphtheria-tetanus-pertussis vaccine for the outcome of paediatric admissions? A hospital based observational study from Guinea-Bissau. Vaccine. 2017;35(50):7018–7025. doi: 10.1016/j.vaccine.2017.10.047.
    1. Benn CS, Diness BR, Roth A, et al. Effect of 50,000 IU vitamin A given with BCG vaccine on mortality in infants in Guinea-Bissau: randomised placebo controlled trial. BMJ. 2008;336(7658):1416–1420. doi: 10.1136/.
    1. Benn CS, Bale C, Sommerfelt H, et al. Hypothesis: vitamin A supplementation and childhood mortality: amplification of the non-specific effects of vaccines? Int J Epidemiol. 2003;32(5):822–828. doi: 10.1093/ije/dyg208.
    1. Benn CS, Aaby P, Arts RJ, et al. An enigma: why vitamin A supplementation does not always reduce mortality even though vitamin A deficiency is associated with increased mortality. Int J Epidemiol. 2015;44(3):906–918. doi: 10.1093/ije/dyv117.
    1. 46(2): 695–705. doi: 10.1093/ije/dyw120
    1. Aaby P, Gustafson P, Roth A, et al. Vaccinia scars associated with better survival for adults. An observational study from Guinea-Bissau. Vaccine. 2006;4(29–30):5718–5725. doi: 10.1016/j.vaccine.2006.04.045.
    1. Rieckmann A, Villumsen M, Sørup S, et al. Vaccinations against smallpox and tuberculosis are associated with better long-term survival: a Danish case-cohort study 1971-2010. Int J Epidemiol 2017; 46(2): 695–705. 10.1093/ije/dyw120.

Source: PubMed

赞助者和合作者

医疗条件

药物干预

3
订阅